FDA 483 - Denison Pharmaceuticals, LLC - February 09, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Denison Pharmaceuticals, LLC received a Form 483 citing nine observations related to significant quality control and manufacturing deficiencies. The firm failed to thoroughly investigate numerous product quality complaints, adverse events, and out-of-specification results, including microbial contamination and container closure integrity issues. Additionally, the inspection revealed inadequate validation of test methods and manufacturing processes, poor sanitation practices, and a failure to complete corrective and preventive actions within established timeframes.
ID · a5fe71a4-9389-46f4-9317-5e90e0d763eb